Feasibility And Safety Study Of rhBMP-2/CPM For Hip Fractures

Phase 2 Completed 108 enrolled Wyeth is now a wholly owned subsidiary of Pfizer

RandomizedParallel-groupSingle-blindTreatment

Summary

The primary objective of this study is to assess the safety of administering rhBMP-2/CPM as an adjuvant to internal fixation in subjects with fractures of the proximal femur.

Timeline

Start: 2006-12
Primary completion: 2010-06
Completion: 2010-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	rhBMP-2	Protein / enzyme biologic	1 mg/ml	Other
Subject	rhBMP-2	Protein / enzyme biologic	2 mg/ml	Other

Indications

No indication recorded.